Replies to post #228059 on Biotech Values

[DewDiligence]

BMY settles Revlimid US-patent litigation with RDY:

https://finance.yahoo.com/news/bristol-myers-squibb-announces-settlement-105900202.html

RDY’s earliest US-launch date is undisclosed, but it’s later than the Mar 2022 launch date for Natco, the first generic-drug company to settle with BMY on the Revlimid patent.